p50

Mangiferin (Hedysarid) is used for antidiabetes. Extracted from Mangifera indica L.

1. Kamebakaurin (Kamebakaurine) has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress. 2. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. 3. Kamebakaurin has anti-cancer and anti-inflammatory activities through direct inhibition of DNA-binding activity of nuclear factor-kappa B (NF-κB) p50.4. Kamebakaurin has anti-neuroinflammatory activity via inhibition of c-Jun NH -terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells.

VTP50469 is a highly selective and orally active small molecule inhibitor of the Menin-MLL protein-protein interaction with potent anti-leukemic activity with a Ki of 104 pM.

VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity.

PAP508 is a PROTAC specifically targeting AR (Androgen Receptor).

QP5020 is a QPCTL inhibitor with an IC50 value of 15 nM, demonstrating antitumor efficacy.

QP5038 is an inhibitor of QPCTL, exhibiting an IC50 value of 3.8 nM. It also possesses antitumor properties.

P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage.

RP5063 Hydrochloride is a modulator of multimodal serotonin receptors.

SHP504 is an inhibitor of SHP2 phosphatase and acts on SHP21-525 (IC50: 21 μM).

CBP501 is a peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.

VTP-50469 is a novel, potent, selective, orally-available MeninMLL1 inhibitor, being effectively against MLL-rearranged and NPM1c+ leukemia, selectively killing cell lines with MLLrearrangements and NPM1c+ mutations.

PRMT5:MEP50 PPI, a pioneering inhibitor of the PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI), demonstrates anti-tumor and anti-proliferative effects in lung and prostate cancer cells.

CBP501 Affinity Peptide, a Chk kinase inhibitor, disrupts G2 arrest triggered by DNA-damaging agents and is utilized in cancer research [1].

ASP5094 is a humanized anti-integrin α9 monoclonal antibody. It exhibits excellent safety and tolerability. ASP5094 can be utilized in the research of diseases such as rheumatoid arthritis.

TP508 is a 23 amino acid synthetic peptide representing residues 508-530 of human prothrombin which is identified as a potential receptor-binding domain based on competition for high-affinity thrombin binding to fibroblasts.TP508 (Chrysalin) is an investi

TP508 TFA is a nonproteolytic thrombin peptide. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates the production of NO in human endothelial cells. It activates endothelial cells and stem cells to revascularize and regenerates tissues.

DP50 is a bifunctional compound containing both an opioid receptor agonist (MOP) and a neuropeptide FF receptor (NPFFR) antagonist. It can be utilized in studies related to analgesia.

Rusalatide acetate (TP508 amide acetate), a regenerative peptide, mitigates radiation-induced gastrointestinal injury by activating stem cells and preserving mucosal integrity.

Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases.

LLY-283 is a potent, selective, and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, exhibiting an IC50 of 22 nM and a Kd of 6 nM for the PRMT5:MEP50 complex, and demonstrates antitumor activity.

CP-506 (compound 26) mesylate is an anticancer compound serving as a substrate for nitroreductase and CYP reductase. It exhibits anticancer activity.

AP-503 is a selective agonist of GPR133/ADGRD1, with an EC50 of 1.21 nM. It is utilized in research for preventing muscle-related disorders and vestibular dysfunction diseases.

NIP 502 is a diazinone derivative that exhibits oral anti-inflammatory and immunosuppressive properties. It is useful for research related to asthma.